A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed · Phase 2 · Has a placebo group

Conditions studied: HIV-1-infection, Elevated Cardiovascular Risk

In brief

The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.

Key facts

Study ID
NCT05630885
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
110
Starts
2023-05-30
Expected to finish
2024-06-19
Last updated by the study team
2025-07-16

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.